Abstract
Tenofovir, a nucleotide analog, is one of the first-line medications recommended for the treatment of active chronic hepatitis B virus infection (CHB) and as a primary prophylaxis to prevent hepatitis B reactivation in cases of immunosuppression. We report the first case of tenofovir-induced leukocytoclastic vasculitis (LCV). A 43-year-old obese woman, who was known to have inactive CHB, was diagnosed with chronic immune thrombocytopenic purpura (ITP). She was treated with corticosteroid therapy and was put on tenofovir to prevent hepatitis B virus reactivation. A month later, she developed a skin rash, described as non-blanchable well-defined erythematous to violaceous papules and targetoid patches in her lower extremities. A skin biopsy showed features of LCV. The rash resolved completely within few days after replacing tenofovir with entecavir.
| Original language | English |
|---|---|
| Pages (from-to) | 429-431 |
| Number of pages | 3 |
| Journal | Oman Medical Journal |
| Volume | 32 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Sep 1 2017 |
Fingerprint
Keywords
- Hepatitis B
- Leukocytoclastic vasculitis
- Tenofovir
ASJC Scopus subject areas
- Medicine(all)
Cite this
Tenofovir-induced leukocytoclastic vasculitis. / Al-Busafi, Said A.; Al-Suleimani, Abdulatif; Al-Hamadani, Aysha; Rasool, Wasif.
In: Oman Medical Journal, Vol. 32, No. 5, 01.09.2017, p. 429-431.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tenofovir-induced leukocytoclastic vasculitis
AU - Al-Busafi, Said A.
AU - Al-Suleimani, Abdulatif
AU - Al-Hamadani, Aysha
AU - Rasool, Wasif
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Tenofovir, a nucleotide analog, is one of the first-line medications recommended for the treatment of active chronic hepatitis B virus infection (CHB) and as a primary prophylaxis to prevent hepatitis B reactivation in cases of immunosuppression. We report the first case of tenofovir-induced leukocytoclastic vasculitis (LCV). A 43-year-old obese woman, who was known to have inactive CHB, was diagnosed with chronic immune thrombocytopenic purpura (ITP). She was treated with corticosteroid therapy and was put on tenofovir to prevent hepatitis B virus reactivation. A month later, she developed a skin rash, described as non-blanchable well-defined erythematous to violaceous papules and targetoid patches in her lower extremities. A skin biopsy showed features of LCV. The rash resolved completely within few days after replacing tenofovir with entecavir.
AB - Tenofovir, a nucleotide analog, is one of the first-line medications recommended for the treatment of active chronic hepatitis B virus infection (CHB) and as a primary prophylaxis to prevent hepatitis B reactivation in cases of immunosuppression. We report the first case of tenofovir-induced leukocytoclastic vasculitis (LCV). A 43-year-old obese woman, who was known to have inactive CHB, was diagnosed with chronic immune thrombocytopenic purpura (ITP). She was treated with corticosteroid therapy and was put on tenofovir to prevent hepatitis B virus reactivation. A month later, she developed a skin rash, described as non-blanchable well-defined erythematous to violaceous papules and targetoid patches in her lower extremities. A skin biopsy showed features of LCV. The rash resolved completely within few days after replacing tenofovir with entecavir.
KW - Hepatitis B
KW - Leukocytoclastic vasculitis
KW - Tenofovir
UR - http://www.scopus.com/inward/record.url?scp=85030770967&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030770967&partnerID=8YFLogxK
U2 - 10.5001/omj.2017.80
DO - 10.5001/omj.2017.80
M3 - Article
VL - 32
SP - 429
EP - 431
JO - Oman Medical Journal
JF - Oman Medical Journal
SN - 1999-768X
IS - 5
ER -